SYED ZAIDI: Open Payments
NPI 1225242647 · PINELLAS PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,855 in 139 payments from 16 companies in 2025. Trend: 2023 $909 · 2024 $1,228 · 2025 $2,855
Food & beverage: $2,855
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $424 |
| Alkermes, Inc. | 19 | $380 |
| ABBVIE INC. | 12 | $314 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $313 |
| Otsuka America Pharmaceutical, Inc. | 11 | $238 |
| E.R. Squibb & Sons, L.L.C. | 12 | $220 |
| Supernus Pharmaceuticals, Inc. | 13 | $207 |
| Teva Pharmaceuticals USA, Inc. | 13 | $196 |
| Indivior Inc. | 9 | $189 |
| Lundbeck LLC | 6 | $120 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, ARISTADA, REXULTI, COBENFY, Qelbree, SUBLOCADE.
Industry payments across FL — which companies pay providers there.
